1 – 18 of 18
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden
(
- Contribution to journal › Article
-
Mark
Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)
(
- Contribution to journal › Article
-
Mark
EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update
(
- Contribution to journal › Article
- 2021
-
Mark
Venous thromboembolism in ANCA-associated vasculitis : A population-based cohort study
(
- Contribution to journal › Article
- 2019
-
Mark
Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden
(
- Contribution to journal › Published meeting abstract
- 2017
-
Mark
Rate of comorbidities in giant cell arteritis : A population-based study
(
- Contribution to journal › Article
-
Mark
Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
- 2016
-
Mark
Comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis versus the general population
(
- Contribution to journal › Article
-
Mark
Visual complications in patients with biopsy-proven giant cell arteritis : A population-based study
(
- Contribution to journal › Article
- 2015
-
Mark
Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.
(
- Contribution to journal › Article
- 2013
-
Mark
Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis
(
- Contribution to journal › Article
- 2011
-
Mark
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
(
- Contribution to journal › Article
-
Mark
A Model to Predict Cardiovascular Events in Patients With Newly Diagnosed Wegener's Granulomatosis and Microscopic Polyangiitis
(
- Contribution to journal › Article
- 2010
-
Mark
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis
(
- Contribution to journal › Article
- 2008
-
Mark
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial
(
- Contribution to journal › Article
- 2007
-
Mark
Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis - A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
(
- Contribution to journal › Article